Sanofi Pasteur's Fluzone Quadrivalent vaccine 0.5mL Dose Approved for Children 6 Months of Age and Older (January 2019)


Sanofi Pasteur and CCPA Purchsang Partners are excited to inform our members that as of January 23 2019, Sanofi Pasteur's Fluzone Quadrivalent Vaccine 0.5mL Dose has been approved to be used in children 6 months of age and older. This new option offers health care providers the simplicity of using the same 0.5mL dose for all eligible children when immunizing against the flu.

Please review the information below as well as the  Customer Letter from Sanofi Pasteur  regarding this important update and the Updated Prescribing Information for Fluzone Quadrivalent 0.5 mL.

  • Fluzone Quadrivalent 0.5mL dose is currently available to reserve for the 2019-2020 influenza season.
  • This approval is supported by clinical data from a Phase IV safety and immunogenicity study conducted in nearly 2,000 children, which demonstrated that one or two doses of 0.5 mL of vaccine in children 6 through 35 months of age had a safety profile that was comparable to one or two doses of 0.25 mL of vaccine with no new safety concerns observed, and induced a robust immune response.
  • Fluzone Quadrivalent 0.25mL dose will still be available to order for children ages 6-35 months for the 2019-2020 season.
  • CPT codes and payer coverage will not be affected by this new approval.

Please also keep an eye out for CCPA Purchasing Partner's 2019-2010 Fluzone Agreement Announcement in the upcoming weeks! Members will receive an email with the information and link to the 2019-2020 pricing.


« Back